诺和诺德股价因阿尔茨海默症药物semaglutide两项试验失败而暴跌8%
Novo shares tumble after 2 trial misses for semaglutide in Alzheimer's disease
#Alzheimer disease#Novo Nordisk#trial misses#Novo shares#Alzheimer
生命科学资讯
生物技术与制药领域的最新动态
诺和诺德药物Amycretin在二期糖尿病试验中减轻体重并降低血糖
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
诺和诺德司美格鲁肽在三期阿尔茨海默症试验中未达预期
Novo’s semaglutide fails in phase III Alzheimer’s trials
#phase III#III Alzheimer#Novo Nordisk#treat Alzheimer#receptor agonist
诺和诺德GLP-1药物在备受关注的阿尔茨海默症研究中未达目标
Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s studies
#Novo Nordisk#watched Alzheimer#misses goal#heart health#combat neurodegeneration
诺和诺德公司的司美格鲁肽在备受关注的阿尔茨海默病试验中未达预期
Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials
#Novo Nordisk#closely-watched Alzheimer#long shot#long shots#Nordisk semaglutide
诺和、礼来开始直接向雇主销售减肥药物
Novo, Lilly begin to sell obesity medications directly to employers
#Novo Nordisk#Eli Lilly#employers Building#Lilly begin#weight loss
2025-2033年生物技术市场治疗创新与预测报告：聚焦龙沙、安进、先正达、百康、百健、罗氏、诺华、诺和诺德、辉瑞及西雅图遗传学公司 - ResearchAndMarkets.com - 商业电讯
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and Seagen - ResearchAndMarkets.com - Business Wire
#Therapeutic Innovations#Forecast Report#Featuring Lonza#Novo Nordisk#Market Therapeutic